Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06112847 · ClinicalTrials.gov registry record · Phase 2
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
A Phase 2 study, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT06112847 is a Phase 2 study that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 29 participants.
The verdict
NCT06112847, a Phase 2 study, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase II trial tests how well lenalidomide and epcoritamab works in treating patients with follicular lymphoma that has not been previously treated. Although follicular lymphoma is incurable, prognosis has improved for both early and advanced stage disease, largely attributed to therapeutic advances. Lenalidomide may stimulate or suppress the immune system in different ways and stop cancer cells from growing and by preventing the growth of new blood vessels that cancer cells need to grow. Epcoritamab is a bispecific monoclonal antibody that binds to two different antigens (the part of the target that the antibody attaches to), at the same time. This dual action allows bispecific antibodies to improve target specificity by binding two antigens on the same cell to recruit and activate immune cells to kill cancer cells. Lenalidomide and epcoritamab, when given together, may be more effective in treating patients with follicular lymphoma than if they were given alone.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Bone Marrow Biopsy
- PROCEDURE Computed Tomography
- OTHER Electronic Health Record Review
- BIOLOGICAL Epcoritamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2024-01-24 |
| Est. Completion | 2026-07-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06112847
The ClinicalTrials.gov registry entry for NCT06112847 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06112847 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06112847 about?
NCT06112847 is a clinical study titled "Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma". This phase II trial tests how well lenalidomide and epcoritamab works in treating patients with follicular lymphoma that has not been previously treated. Although follicular lymphoma is incurable, prognosis has improved for both early and advanced stage disease, largely attributed to therapeutic adv...
What is the current status of trial NCT06112847?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2024-01-24. Estimated completion is 2026-07-17.
What interventions are being tested in trial NCT06112847?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Bone Marrow Biopsy (PROCEDURE), Computed Tomography (PROCEDURE), Electronic Health Record Review (OTHER), Epcoritamab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06112847?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.